Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-109 in EGFR Exon 20 Insertion Mutated NSCLC
NCT06706713Phase 2Recruiting
- Sponsor
- BeBetter Med
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of BEBT-109 in non-small cell lung cancer (NSCLC), sponsored by BeBetter Med. Started Apr 2022; status: recruiting.
02
Drugs
BEBT-109
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06706713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706713.